Interstitial Lung Disease Registry Study: Prospective and Retrospective Observational Study in Austria

Recruiting

• Conditions: Interstitial Lung Disease

• Registration Number: NCT06522334
• Lead Sponsor: Ludwig Boltzmann Institute for Lung Health

Brief Summary

The goal of this registry is to systematically record epidemiological and clinical data throughout the whole interstitial lung disease course - starting with the diagnosis, therapy, follow up of lung function, symptom control, adverse events, medication, survival and death.

There are no additional interventions regarding this registry.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-02-28
• Study First Submitted: 2024-07-22
• Study First Submitted QC: 2024-07-22
• Study First Posted: 2024-07-26
• Status Verified: 2025-03
• Last Update Submitted: 2025-03-11
• Last Update Posted: 2025-03-14
• Primary Completion: 2034-02-28
• Study Completion: 2034-02-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• diagnosis of interstitial lung disease
• written informed consent

Exclusion Criteria

• to not comprehend and rightfully judge participation

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Mortality	10 years	Mortality caused by interstitial lung disease
Loss of lung function	2 years	FVC and DLCO loss within 24 months

Secondary Outcome Measures

Name	Time	Method
Response to drugs	10 years	Response to immunosuppressive/immunomodulating/antifibrotic drugs
Prevalence	10 years	Prevalence of the different interstitial lung diseases in Austria

Trial Locations

Locations (5)

Klinik Hietzing; 🇦🇹 Wien, Austria

Klinik Penzing; 🇦🇹 Wien, Austria

Ludwig Boltzmann Institut for Lung Health; 🇦🇹 Wien, Austria

Klinik Ottakring; 🇦🇹 Wien, Austria

Klinik Floridsdorf; 🇦🇹 Wien, Austria